Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02118337 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

A Phase 1 study of Kidney Cancer and Clear Cell Renal Cell Carcinoma, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
97
Enrollment target
20
Study locations

NCT02118337 is a Phase 1 study of Kidney Cancer and Clear Cell Renal Cell Carcinoma that has completed, run by MedImmune. The registered enrollment target is 97 participants, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02118337, a Phase 1 study of Kidney Cancer and Clear Cell Renal Cell Carcinoma, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
97 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.

Conditions Studied

Kidney Cancer Clear Cell Renal Cell Carcinoma Select Advanced Malignancies

Interventions

  • BIOLOGICAL Durvalumab
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL MEDI0680

Study Locations (20)

Other

  • Research Site - East Bentleigh
  • Research Site - Frankston
  • Research Site - Bordeaux
  • Research Site - Dijon
  • Research Site - Marseille

California

  • Research Site - Los Angeles

Florida

  • Research Site - Tampa

Kansas

  • Research Site - Overland Park

Kentucky

  • Research Site - Louisville

Minnesota

  • Research Site - Rochester

New Jersey

  • Research Site - Hackensack

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2014-05-19
Est. Completion 2020-03-17
Phase Phase 1

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02118337

The ClinicalTrials.gov registry entry for NCT02118337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (89% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.

NCT02118337 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02118337 about?

NCT02118337 is a clinical study titled "A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies". To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.

What is the current status of trial NCT02118337?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2014-05-19. Estimated completion is 2020-03-17.

What conditions does trial NCT02118337 study?

This clinical trial studies the following conditions: Kidney Cancer, Clear Cell Renal Cell Carcinoma, Select Advanced Malignancies.

What interventions are being tested in trial NCT02118337?

The interventions under investigation include: Durvalumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), MEDI0680 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02118337?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02118337 being conducted?

This trial has 20 study locations across California, Florida, Kansas, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kidney Cancer

All registered trials for this condition

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.